Migräne in speziellen hormonellen Situationen

ZUSAMMENFASSUNG

Bei der menstruellen Migräne gibt es verschiedene spezifische Therapieoptionen. So kann ca. 4–5 Tage vor dem erwarteten Menstruationsbeginn ein Östradiolpflaster mit 50 µg pro Tag für wenigstens 7 Tage als Kurzzeitprophylaxe ausprobiert werden; bei Unwirksamkeit kann dies mit 100 µg pro Tag wiederholt werden. Eine hormonelle Kontrazeption mit einem Mischpräparat oder Mehrphasenpräparat kann probatorisch abgesetzt werden. In besonderen Fällen ist eine durchgehende hormonelle Kontrazeption bis zu 2 Jahre sinnvoll.

Patientinnen mit Migräne und Endometriose zeigen während der Menstruation höhere CGRP-Werte als in der Zyklusmitte, wohingegen dies bei Frauen ohne Migräne und Kontrollprobandinnen umgekehrt ist. Dies deutet auf eine mögliche Rolle von CGRP in den perimenstruellen Schmerzattacken hin. Weiterhin ist die Lebensqualität bei Patientinnen mit Migräne und Endometriose deutlich stärker beeinträchtigt als bei nur einer Erkrankung. Daher ist es klinisch relevant, diese Komorbidität zu berücksichtigen.

Eine hormonelle Frau-zu-Mann-Transition geht mit signifikant mehr Kopfschmerzen einher als die umgekehrte Transition. Bei der Mann-zu-Frau-Transition scheint sich dagegen häufiger eine Migräne zu bilden, insbesondere mit Aura. Die Behandlung der Kopfschmerzen und der Migräne erfolgt wie bei anderen Betroffenen auch, allerdings muss die erhöhte Thromboseneigung durch die Hormonbehandlung berücksichtigt werden.

ABSTRACT

There are different specific treatment options for menstrual migraine. About 4–5 days before the expected onset of menstruation, an estradiol patch (50 µg) can be applied for 7 days as short term prophylaxis; if this is not effective, it can be repeated with a 100 µg patch. Stopping a hormonal contraception with a combination pill or with a biphasic pill can be tried to improve menstrual migraine. In specific situations, an ongoing hormonal contraception for up to 2 years can also be tried.

Women with migraine and endometriosis show elevated CGRP-levels in the middle of the menstrual cycle, whereas women without migraine show a reverse pattern. This points to a role of CGRP in the perimenstrual pain attack. Further, quality of life of patients with migraine and endometriosis is much more impaired than of patients with only one disorder. Therefore, it is clinically relevant to consider endometriosis in the consulting of women with migraine.

A hormonal female-to-male transition shows significantly more headache than vice versa. In people with male-to-female transition, there is evidence for an increased risk for migraine, in particular for migraine with aura. The treatment of headache and migraine in transsexual people follows the normal treatment guidelines but has to consider the increased risk of thrombosis by hormonal treatment.

Schlüsselwörter

Menstruelle Migräne - Kurzzeitprophylaxe - Endometriose - Transsexualität

Key words

Menstrual migraine - short term prophylaxis - endometriosis - transsexual

Publikationsverlauf

Artikel online veröffentlicht:
31. Mai 2023

• Literatur

• 1 Victor TW, Hu X, Campbell JC. et al Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 2010; 30: 1065-1072 DOI: 10.1177/0333102409355601.
• 2 Abu-Arafeh I, Razak S, Sivaraman B. et al Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol 2010; 52: 1088-1097 DOI: 10.1111/j.1469-8749.2010.03793.x.
• 3 Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis – part I. Headache 2006; 46: 3-23 DOI: 10.1111/j.1526-4610.2006.00309.x.
• 4 Böttcher B, Kyprianou A, Lechner C. et al Manifestation of migraine in adolescents: Does it change in puberty?. Eur J Paediatr Neurol 2020; 26: 29-33 DOI: 10.1016/j.ejpn.2020.02.006.
• 5 Silberstein SD. The role of sex hormones in headache. Neurology 1992; 42: 37-42
• 6 Welch KM. Migraine and ovarian steroid hormones. Cephalalgia 1997; 17 (Suppl. 20) 12-16 DOI: 10.1177/0333102497017s2005.
• 7 MacGregor EA, Victor TW, Hu X. et al Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache 2010; 50: 528-538 DOI: 10.1111/j.1526-4610.2010.01625.x.
• 8 Kim M, Blanchard EB. Two studies of the non-pharmacological treatment of menstrually-related migraine headaches. Headache 1992; 32: 197-202 DOI: 10.1111/j.1526-4610.1992.hed3204197.x.
• 9 de Lignieres B, Vincens M, Mauvais-Jarvis P. et al Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res Ed) 1986; 293: 1540 DOI: 10.1136/bmj.293.6561.1540.
• 10 Dennerstein L, Morse C, Burrows G. et al Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988; 02: 113-120 DOI: 10.3109/09513598809023619.
• 11 Smite MG, Meer YGvd, Pfeil J. et al Perimenstrual Migraine: Effect of Estraderm TTS(r) and the Value of Contingent Negative Variation and Exteroceptive Temporalis Muscle Suppression Test. Headache 1994: 34
• 12 Murray SC, Muse KN. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and „add-back“ therapy. Fertil Steril 1997; 67: 390-393 DOI: 10.1016/s0015-0282(97)81928-0.
• 13 Martin V, Wernke S, Mandell K. et al Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache. Headache 2003; 43: 309-321 DOI: 10.1046/j.1526-4610.2003.03065.x.
• 14 Facchinetti F, Bonellie G, Kangasniemi P. et al The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. Obstet Gynecol 1995; 86: 911-916 DOI: 10.1016/0029-7844(95)00288-3.
• 15 Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol 1993; 82: 769-772
• 16 Gross M, Barrie M, Bates D, Dowson A, Elrington G. The efficacy of sumatriptan in menstrual migraine. Eur J Neurol. 1995; 02: 144-5
• 17 Savi L, Omboni S, Lisotto C. et al Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. J Headache Pain 2011; 12: 609-615 DOI: 10.1007/s10194-011-0366-9.
• 18 Bartolini M, Giamberardino MA, Lisotto C. et al Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. J Headache Pain 2012; 13: 401-406 DOI: 10.1007/s10194-012-0455-4.
• 19 Cady RK, Diamond ML, Diamond MP. et al Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache 2011; 51: 664-673 DOI: 10.1111/j.1526-4610.2011.01894.x.
• 20 Mannix LK, Savani N, Landy S. et al Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007; 47: 1037-1049 DOI: 10.1111/j.1526-4610.2007.00855.x.
• 21 Allais G, Bussone G, Tullo V. et al Frovatriptan 2.5 mg plus dexketoprofen (25 mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial. Cephalalgia 2015; 35: 45-50 DOI: 10.1177/0333102414542290.
• 22 Bigal M, Sheftell F, Tepper S. et al A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache 2008; 48: 1286-1293 DOI: 10.1111/j.1526-4610.2008.01092.x.
• 23 Mathew NT. Cyclic prophylactic treatment of menstrual migraine using naproxen and ergotamine. Headache 1986; 26: 314
• 24 Sances G, Martignoni E, Fioroni L. et al Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990; 30: 705-709 DOI: 10.1111/j.1526-4610.1990.hed3011705.x.
• 25 Facchinetti F, Sances G, Borella P. et al Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991; 31: 298-301 DOI: 10.1111/j.1526-4610.1991.hed3105298.x.
• 26 Brandes JL, Poole A, Kallela M. et al Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009; 29: 1133-1148 DOI: 10.1111/j.1468-2982.2009.01840.x.
• 27 MacGregor EA, Brandes JL, Silberstein S. et al Safety and tolerability of short-term preventive frovatriptan: a combined analysis. Headache 2009; 49: 1298-1314 DOI: 10.1111/j.1526-4610.2009.01513.x.
• 28 Moschiano F, Allais G, Grazzi L. et al Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurol Sci 2005; 26 (Suppl. 02) s162-166 DOI: 10.1007/s10072-005-0435-4.
• 29 Newman L, Mannix LK, Landy S. et al Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 2001; 41: 248-256 DOI: 10.1046/j.1526-4610.2001.111006248.x.
• 30 Silberstein SD, Berner T, Tobin J. et al Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation. Headache 2009; 49: 1283-1297 DOI: 10.1111/j.1526-4610.2009.01509.x.
• 31 Silberstein SD, Elkind AH, Schreiber C. et al A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004; 63: 261-269 DOI: 10.1212/01.wnl.0000134620.30129.d6.
• 32 Brandes JL, Smith T, Diamond M. et al Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine. Headache 2007; 47: 886-894 DOI: 10.1111/j.1526-4610.2007.00809.x.
• 33 Tuchman MM, Hee A, Emeribe U. et al Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs 2008; 22: 877-886 DOI: 10.2165/00023210-200822100-00007.
• 34 Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology 2008; 70: 1555-1563 DOI: 10.1212/01.wnl.0000310638.54698.36.
• 35 MacGregor EA, Frith A, Ellis J. et al Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 2006; 67: 2159-2163 DOI: 10.1212/01.wnl.0000249114.52802.55.
• 36 Smits MG, van der Meer YG, Pfeil JP. et al Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache 1994; 34: 103-106 DOI: 10.1111/j.1526-4610.1994.hed3402103.x.
• 37 Pfaffenrath V. Efficacy and safety of percutaneous estradiol vs placebo in menstrual migraine. Cephalalgia 1993; 13 (Suppl. 13) 244
• 38 Pradalier A, Vincent D, Beaulieu P. et al Correlation between oes-tradiol plasma level and therapeutic effect on menstrual migraine. In: Clifford Rose F, ed. New advances in headache research. Vol 4. London: Smith-Gordon; 1994: 129-132
• 39 Almén-Christensson A, Hammar M, Lindh-Åstrand L. et al Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study. Fertil Steril 2011; 96: 498-500.e491 DOI: 10.1016/j.fertnstert.2011.05.089.
• 40 Magos AL, Zilkha KJ, Studd JW. Treatment of menstrual migraine by oestradiol implants. J Neurol Neurosurg Psychiatry 1983; 46: 1044-1046 DOI: 10.1136/jnnp.46.11.1044.
• 41 Ornello R, Frattale I, Caponnetto V. et al Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series. Brain Sci 2021: 11 DOI: 10.3390/brainsci11030370
• 42 Nelles G, Schmitt L, Humbert T. et al Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting. J Headache Pain 2010; 11: 33-44 DOI: 10.1007/s10194-009-0163-x.
• 43 Pavlovic JM, Paemeleire K, Göbel H. et al Efficacy and safety of erenumab in women with a history of menstrual migraine. J Headache Pain 2020; 21: 95 DOI: 10.1186/s10194-020-01167-6.
• 44 Reid RL, Fortier MP, Smith L. et al Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception 2010; 82: 497-502 DOI: 10.1016/j.contraception.2010.06.002.
• 45 Teichmann A, Apter D, Emerich J. et al Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Contraception 2009; 80: 504-511 DOI: 10.1016/j.contraception.2009.05.128.
• 46 Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007; 75: 444-449 DOI: 10.1016/j.contraception.2007.01.014.
• 47 Sulak P, Willis S, Kuehl T. et al Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 2007; 47: 27-37 DOI: 10.1111/j.1526-4610.2007.00650.x.
• 48 Lichten EM, Bennett RS, Whitty AJ. et al Efficacy of danazol in the control of hormonal migraine. J Reprod Med 1991; 36: 419-424
• 49 O‘Dea JP, Davis EH. Tamoxifen in the treatment of menstrual migraine. Neurology 1990; 40: 1470-1471 DOI: 10.1212/wnl.40.9.1470.
• 50 Bulun SE. Endometriosis. N Engl J Med 2009; 360: 268-279 DOI: 10.1056/NEJMra0804690.
• 51 Simoens S, Dunselman G, Dirksen C. et al The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod 2012; 27: 1292-1299 DOI: 10.1093/humrep/des073.
• 52 Ferrero S, Pretta S, Bertoldi S. et al Increased frequency of migraine among women with endometriosis. Hum Reprod 2004; 19: 2927-2932 DOI: 10.1093/humrep/deh537.
• 53 Tietjen GE, Conway A, Utley C. et al Migraine is associated with menorrhagia and endometriosis. Headache 2006; 46: 422-428 DOI: 10.1111/j.1526-4610.2006.00290.x.
• 54 Adewuyi EO, Sapkota Y, International Endogene Consortium I. et al Shared Molecular Genetic Mechanisms Underlie Endometriosis and Migraine Comorbidity. Genes (Basel) 2020: 11 DOI: 10.3390/genes11030268
• 55 Gupta D, Hull ML, Fraser I. et al Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev 2016; 04: Cd012165 DOI: 10.1002/14651858.Cd012165.
• 56 Yan D, Liu X, Guo SW. Neuropeptides Substance P and Calcitonin Gene Related Peptide Accelerate the Development and Fibrogenesis of Endometriosis. Sci Rep 2019; 09: 2698 DOI: 10.1038/s41598-019-39170-w.
• 57 Raffaelli B, Overeem LH, Mecklenburg J. et al Plasma calcitonin gene-related peptide (CGRP) in migraine and endometriosis during the menstrual cycle. Ann Clin Transl Neurol 2021; 08: 1251-1259 DOI: 10.1002/acn3.51360.
• 58 Aloisi AM, Bachiocco V, Costantino A. et al Cross-sex hormone administration changes pain in transsexual women and men. Pain 2007; 132 (Suppl. 01) S60-s67 DOI: 10.1016/j.pain.2007.02.006.
• 59 Hranilovich JA, Kaiser EA, Pace A. et al Headache in transgender and gender-diverse patients: A narrative review. Headache 2021; 61: 1040-1050 DOI: 10.1111/head.14171.
• 60 Pringsheim T, Gooren L. Migraine prevalence in male to female transsexuals on hormone therapy. Neurology 2004; 63: 593-594 DOI: 10.1212/01.wnl.0000130338.62037.cc.
• 61 Yalinay Dikmen P, Ertas M, Kosak S. et al Primary headaches among gender dysphoric female-to-male individuals: A cross-sectional survey on gender transition experience. Headache 2021; 61: 1194-1206 DOI: 10.1111/head.14203.
• 62 Nguyen HV, Gilbert AL, Fortin E. et al Elevated Intracranial Pressure Associated With Exogenous Hormonal Therapy Used for Gender Affirmation. J Neuroophthalmol 2021; 41: 217-223 DOI: 10.1097/wno.0000000000000926.
• 63 Sacco S, Ricci S, Degan D. et al Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain 2012; 13: 177-189 DOI: 10.1007/s10194-012-0424-y.
• 64 Diener HC, Gaul C, Kropp P.. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, 2018. In: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. www.dgn.org/leitlinien (abgerufen am 5.5.2023)
• 65 Aegidius K, Zwart JA, Hagen K. et al Oral contraceptives and increased headache prevalence: the Head-HUNT Study. Neurology 2006; 66: 349-353
• 66 Nappi RE, Terreno E, Sances G. et al Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception 2013; 88: 369-375
• 67 Sulak PJ, Willis SA, Kuehl TJ. et al Headaches and Oral Contraceptives: Impact of Eliminating the Standard 7-Day Placebo Interval. Headache: The Journal of Head and Face Pain 2007: 47
• 68 Morotti M, Remorgida V, Venturini PL. et al Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. Eur J Obstet Gynecol Reprod Biol 2014; 179: 63-68 DOI: 10.1016/j.ejogrb.2014.05.016.
• 69 Nappi RE, Merki-Feld GS, Terreno E. et al Hormonal contraception in women with migraine: is progestogen-only contraception a better choice?. J Headache Pain 2013; 14: 66
• 70 Somerville BW. The role of progesterone in menstrual migraine. Neurology 1971; 21: 853-859 DOI: 10.1212/wnl.21.8.853.
• 71 Sacco S, Merki-Feld GS, Ægidius KL. et al Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain 2017; 18: 108 DOI: 10.1186/s10194-017-0815-1.
• 72 Burch R. Epidemiology and Treatment of Menstrual Migraine and Migraine During Pregnancy and Lactation: A Narrative Review. Headache 2020; 60: 200-216 DOI: 10.1111/head.13665.